ArticleBlood advances2024

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.

Alberto J Arribas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.